RU2636146C2 - Соединения карбоновых кислот - Google Patents

Соединения карбоновых кислот Download PDF

Info

Publication number
RU2636146C2
RU2636146C2 RU2014151221A RU2014151221A RU2636146C2 RU 2636146 C2 RU2636146 C2 RU 2636146C2 RU 2014151221 A RU2014151221 A RU 2014151221A RU 2014151221 A RU2014151221 A RU 2014151221A RU 2636146 C2 RU2636146 C2 RU 2636146C2
Authority
RU
Russia
Prior art keywords
amino
compound
cancer
pharmaceutically acceptable
formula
Prior art date
Application number
RU2014151221A
Other languages
English (en)
Russian (ru)
Other versions
RU2014151221A (ru
Inventor
Сейдзи ХОРИ
Футоси ХАСЕГАВА
Дайсукэ УРАБЕ
Хиротака КУРЕБАЯСИ
Original Assignee
Сумитомо Дайниппон Фарма Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сумитомо Дайниппон Фарма Ко., Лтд. filed Critical Сумитомо Дайниппон Фарма Ко., Лтд.
Publication of RU2014151221A publication Critical patent/RU2014151221A/ru
Application granted granted Critical
Publication of RU2636146C2 publication Critical patent/RU2636146C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RU2014151221A 2012-05-18 2013-05-17 Соединения карбоновых кислот RU2636146C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648816P 2012-05-18 2012-05-18
US61/648,816 2012-05-18
US201361806158P 2013-03-28 2013-03-28
US61/806,158 2013-03-28
PCT/JP2013/064420 WO2013172479A1 (en) 2012-05-18 2013-05-17 Carboxylic acid compounds

Publications (2)

Publication Number Publication Date
RU2014151221A RU2014151221A (ru) 2016-07-10
RU2636146C2 true RU2636146C2 (ru) 2017-11-21

Family

ID=49583875

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014151221A RU2636146C2 (ru) 2012-05-18 2013-05-17 Соединения карбоновых кислот

Country Status (17)

Country Link
US (5) US9376398B2 (cg-RX-API-DMAC10.html)
EP (1) EP2850067B1 (cg-RX-API-DMAC10.html)
JP (1) JP6184423B2 (cg-RX-API-DMAC10.html)
KR (1) KR102194585B1 (cg-RX-API-DMAC10.html)
CN (1) CN104302628B (cg-RX-API-DMAC10.html)
AU (1) AU2013261267B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014029261A2 (cg-RX-API-DMAC10.html)
CA (1) CA2871589C (cg-RX-API-DMAC10.html)
DK (1) DK2850067T3 (cg-RX-API-DMAC10.html)
ES (1) ES2644702T3 (cg-RX-API-DMAC10.html)
MX (1) MX2014014031A (cg-RX-API-DMAC10.html)
MY (1) MY178053A (cg-RX-API-DMAC10.html)
PH (1) PH12014502524B1 (cg-RX-API-DMAC10.html)
RU (1) RU2636146C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201407115XA (cg-RX-API-DMAC10.html)
TW (1) TWI619704B (cg-RX-API-DMAC10.html)
WO (1) WO2013172479A1 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871589C (en) 2012-05-18 2020-12-22 Seiji Hori Pyrimidine carboxylic acid derivatives and their use as tlr7 agonists
JP6116782B1 (ja) 2015-08-28 2017-04-19 積水メディカル株式会社 ベンジル化合物
HUE055079T2 (hu) * 2015-10-07 2021-10-28 Sumitomo Dainippon Pharma Co Ltd Pirimidin vegyületek
WO2017142871A1 (en) * 2016-02-15 2017-08-24 Astrazeneca Ab Methods comprising fixed intermittent dosing of cediranib
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
CN109715617B (zh) 2016-07-30 2022-04-19 百时美施贵宝公司 作为tlr7、tlr8或tlr9抑制剂的二甲氧基苯基取代的吲哚化合物
ES2902504T3 (es) 2016-09-09 2022-03-28 Bristol Myers Squibb Co Compuestos de indol sustituidos con piridilo
WO2018106606A1 (en) * 2016-12-05 2018-06-14 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
PL3603619T3 (pl) 2017-03-29 2025-11-17 Sumitomo Pharma Co., Ltd. Preparat adjuwantu szczepionkowego
CN110997670B (zh) 2017-08-04 2022-11-01 百时美施贵宝公司 [1,2,4]三唑并[4,3-a]吡啶基取代的吲哚化合物
EP3661926B1 (en) 2017-08-04 2022-02-23 Bristol-Myers Squibb Company Substituted indole compounds useful as inhibitors of tlr7/8/9
CN111448190B (zh) 2017-11-14 2023-09-26 百时美施贵宝公司 取代的吲哚化合物
US12030878B2 (en) 2017-12-15 2024-07-09 Bristol-Myers Squibb Company Substituted indole ether compounds
MX2020006168A (es) 2017-12-18 2020-08-13 Bristol Myers Squibb Co Compuestos de 4-azaindol.
WO2019126081A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
EP3728253B1 (en) 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
EA202091474A1 (ru) 2017-12-19 2020-11-18 Бристол-Маерс Сквибб Компани Замещенные индольные соединения, применимые в качестве ингибиторов tlr
EA202091530A1 (ru) 2017-12-20 2020-09-14 Бристол-Маерс Сквибб Компани Диазаиндольные соединения
JP7287967B2 (ja) 2017-12-20 2023-06-06 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ阻害剤として有効なアミノインドール化合物
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
RU2020124007A (ru) * 2017-12-21 2022-01-21 Сумитомо Дайниппон Фарма Ко., Лтд. Комбинированный препарат, включающий агонист tlr7
JP7351859B2 (ja) * 2018-06-04 2023-09-27 アプロス セラピューティクス， インコーポレイテッド Ｔｌｒ７の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物
AU2019311965B2 (en) 2018-07-23 2026-02-19 Japan Institute For Health Security Composition containing influenza vaccine
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
US12172995B2 (en) 2018-10-24 2024-12-24 Bristol-Myers Squibb Company Substituted indole and indazole compounds
BR112021015577A2 (pt) 2019-02-08 2021-10-05 Research & Business Foundation Sungkyunkwan University Complexo-colesterol agonista do receptor toll-like 7 ou 8 e uso do mesmo
KR102904576B1 (ko) 2019-05-09 2025-12-24 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
CN114829350B (zh) 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
CN115666637A (zh) 2020-03-02 2023-01-31 蛋白科技先锋 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
EP4194008A4 (en) 2020-08-04 2025-01-08 Progeneer Inc. Kinetically acting adjuvant ensemble
WO2022202814A1 (ja) * 2021-03-23 2022-09-29 住友ファーマ株式会社 ピリミジン化合物の製造方法
WO2025110816A1 (ko) 2023-11-23 2025-05-30 프로지니어 주식회사 암의 치료를 위한 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 항암 치료의 병용요법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2343148C2 (ru) * 2002-02-01 2009-01-10 Райджел Фармасьютикалз, Инк Соединения 2,4-пиримидиндиаминов и их применение
WO2009067081A1 (en) * 2007-11-22 2009-05-28 Astrazeneca Ab Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis
WO2010133885A1 (en) * 2009-05-21 2010-11-25 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
WO2012066335A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067269A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012066336A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1375162A (cg-RX-API-DMAC10.html) 1970-10-22 1974-11-27
GB1546937A (en) 1976-07-29 1979-05-31 Beecham Group Ltd 2,4-diaminopyrimidine derivatives
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL78643A0 (en) 1985-05-02 1986-08-31 Wellcome Found Purine derivatives,their preparation and pharmaceutical compositions containing them
DE3603577A1 (de) 1986-02-06 1987-08-13 Joachim K Prof Dr Seydel Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit
JPH08165292A (ja) 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
US6110923A (en) 1994-06-22 2000-08-29 Biochem Pharma Inc. Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
US5736549A (en) 1994-10-05 1998-04-07 Chiroscience Limited Hypoxanthine and guanine compounds
JP4667543B2 (ja) 1996-07-03 2011-04-13 大日本住友製薬株式会社 新規プリン誘導体
JP4375901B2 (ja) 1997-11-28 2009-12-02 大日本住友製薬株式会社 新規な複素環化合物
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
WO1999050249A2 (en) 1998-04-01 1999-10-07 Du Pont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
ES2221414T3 (es) 1998-08-27 2004-12-16 Sumitomo Pharmaceuticals Company, Limited Derivados de pirimidina.
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
AU6111000A (en) 1999-07-22 2001-02-13 Vertex Pharmaceuticals Incorporated Inhibitors of viral helcase
WO2002004449A2 (en) 2000-07-07 2002-01-17 Neotherapeutics, Inc. Methods for treatment of conditions affected by activity of multidrug transporters
JP4331944B2 (ja) 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
AU2003246102A1 (en) 2002-06-27 2004-01-19 Genox Research, Inc. Method of examining allergic disease and drug for treating the same
CA2497765A1 (en) 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Co., Ltd. 8-hydroxy substituted adenine compounds and uses thereof
US7410975B2 (en) 2003-06-20 2008-08-12 Coley Pharmaceutical Group, Inc. Small molecule toll-like receptor (TLR) antagonists
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1667694B1 (en) 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
DE102004012912A1 (de) 2004-03-17 2005-10-13 Daimlerchrysler Ag Tragsäule eines Kraftfahrzeugs
WO2005092892A1 (ja) 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. ８−オキソアデニン化合物
BRPI0509258A8 (pt) 2004-03-26 2019-01-22 Astrazeneca Ab composto de 8-oxoadenina 9-substituída
US7524144B2 (en) 2004-06-22 2009-04-28 Allan Block Corporation Retaining wall
US7585451B2 (en) 2004-12-27 2009-09-08 E.I. Du Pont De Nemours And Company Electroblowing web formation process
KR100700676B1 (ko) 2005-06-24 2007-03-28 (주) 비엔씨바이오팜 6―（4―치환된―아닐리노）피리미딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물
ES2562056T3 (es) * 2005-09-01 2016-03-02 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores P2X3 y P2X2/3
AU2006290465A1 (en) 2005-09-15 2007-03-22 Orchid Research Laboratories Limited Novel pyrimidine carboxamides
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
WO2007034917A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物
JPWO2007034881A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
JPWO2007034882A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
EP1939202A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
EP1939200A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
TW200817391A (en) 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
JP2009542645A (ja) 2006-07-05 2009-12-03 アストラゼネカ・アクチエボラーグ Ｔｌｒ７のモジュレーターとして作用する８−オキソアデニン誘導体
CL2007002231A1 (es) 2006-08-02 2008-04-11 Basf Ag Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
TW200831105A (en) 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
WO2008083465A1 (en) 2007-01-08 2008-07-17 University Health Network Pyrimidine derivatives as anticancer agents
JP5329444B2 (ja) 2007-03-19 2013-10-30 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
EP2132209B8 (en) 2007-03-19 2014-04-16 AstraZeneca AB 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
TW200902018A (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
EP2138497A4 (en) 2007-03-20 2012-01-04 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
BRPI0811125A2 (pt) 2007-05-08 2017-05-09 Astrazeneca Ab imidazoquinolinas com propriedades imunomoduladoras
US7568828B2 (en) 2007-11-05 2009-08-04 Radiant Opto-Electronics Corp. Light guide plate with compensated emission light field
UY31531A1 (es) 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
US20110054168A1 (en) 2008-01-17 2011-03-03 Ayumu Kurimoto Method for preparing adenine compound
US8865896B2 (en) 2008-01-17 2014-10-21 Astrazeneca Aktiebolag Method for preparing adenine compound
CA2739263A1 (en) 2008-10-03 2010-04-08 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors and methods of their use
GB0908772D0 (en) 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
JP4847597B2 (ja) 2010-06-04 2011-12-28 ファナック株式会社 電源回生動作モードの切替機能を有するモータ駆動装置
WO2012067268A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amide compounds and their use in the treatment of disease
CN103370317B (zh) 2010-12-16 2015-10-07 阿斯利康(瑞典)有限公司 可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物
WO2012080730A1 (en) 2010-12-17 2012-06-21 Astrazeneca Ab Purine derivatives
WO2012086336A1 (ja) 2010-12-21 2012-06-28 スズキ株式会社 車両前部の熱交換器懸架構造
CA2871589C (en) * 2012-05-18 2020-12-22 Seiji Hori Pyrimidine carboxylic acid derivatives and their use as tlr7 agonists
RU2020124007A (ru) * 2017-12-21 2022-01-21 Сумитомо Дайниппон Фарма Ко., Лтд. Комбинированный препарат, включающий агонист tlr7

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2343148C2 (ru) * 2002-02-01 2009-01-10 Райджел Фармасьютикалз, Инк Соединения 2,4-пиримидиндиаминов и их применение
WO2009067081A1 (en) * 2007-11-22 2009-05-28 Astrazeneca Ab Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis
JP2011504497A (ja) * 2007-11-22 2011-02-10 アストラゼネカ・アクチエボラーグ 喘息、ｃｏｐｄ、アレルギー性鼻炎、アレルギー性結膜炎、アトピー性皮膚炎、癌、ｂ型肝炎、ｃ型肝炎、ｈｉｖ、ｈｐｖ、細菌感染症および皮膚症の処置のためのピリミジン誘導体
EA201000830A1 (ru) * 2007-11-22 2011-02-28 Астразенека Аб Производные пиримидина для лечения астмы, хобл, аллергического ринита, аллергического конъюнктивита, атопического дерматита, рака, гепатита в, гепатита с, вич, впч, бактериальных инфекций и дерматоза
EA018121B1 (ru) * 2007-11-22 2013-05-30 Астразенека Аб Производные пиримидина для лечения астмы, хобл, аллергического ринита, аллергического конъюнктивита, атопического дерматита, рака, гепатита в, гепатита с, вич, впч, бактериальных инфекций и дерматоза
WO2010133885A1 (en) * 2009-05-21 2010-11-25 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
WO2012066335A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067269A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012066336A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
& JP 2011504497 A & *
JP 2011504497 A & EA 018121 (B1), 2013-05-30 & EA 201000830 (A1) 28.02.2011. *

Also Published As

Publication number Publication date
US10562861B2 (en) 2020-02-18
KR20150023410A (ko) 2015-03-05
EP2850067A4 (en) 2015-11-04
EP2850067A1 (en) 2015-03-25
SG11201407115XA (en) 2014-12-30
MY178053A (en) 2020-09-30
CN104302628A (zh) 2015-01-21
BR112014029261A2 (pt) 2017-06-27
MX2014014031A (es) 2015-02-12
HK1207365A1 (en) 2016-01-29
EP2850067B1 (en) 2017-08-16
JP2015520729A (ja) 2015-07-23
WO2013172479A1 (en) 2013-11-21
US20150099770A1 (en) 2015-04-09
AU2013261267A1 (en) 2014-11-13
AU2013261267A8 (en) 2015-01-22
US11299465B2 (en) 2022-04-12
PH12014502524B1 (en) 2020-10-02
DK2850067T3 (da) 2017-11-06
ES2644702T3 (es) 2017-11-30
PH12014502524A1 (en) 2015-01-12
CA2871589C (en) 2020-12-22
US10150743B2 (en) 2018-12-11
CA2871589A1 (en) 2013-11-21
US12077510B2 (en) 2024-09-03
TW201348212A (zh) 2013-12-01
US9376398B2 (en) 2016-06-28
US20190119220A1 (en) 2019-04-25
US20160251319A1 (en) 2016-09-01
JP6184423B2 (ja) 2017-08-23
KR102194585B1 (ko) 2020-12-23
CN104302628B (zh) 2017-06-23
AU2013261267B2 (en) 2017-06-29
TWI619704B (zh) 2018-04-01
RU2014151221A (ru) 2016-07-10
US20200317623A1 (en) 2020-10-08
US20220267282A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
US12077510B2 (en) Carboxylic acid compounds
ES2386781T3 (es) Procedimiento de preparación de pirimidinas sustituidas y derivados de pirimidina como inhibidores de proteína cinasas
WO2012066335A1 (en) Phenol compounds als toll -like receptor 7 agonists
JP5008778B2 (ja) 新規５−フルオロウラシル誘導体
AU2012298813B2 (en) Inhibitors of Nedd8-activating enzyme
WO2012066336A1 (en) Benzylamine compounds as toll -like receptor 7 agonists
MX2007013780A (es) Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c.
JP2013542916A (ja) 環状アミド化合物および疾患の処置におけるその使用
WO2012067269A1 (en) Aminoalkoxyphenyl compounds and their use in the treatment of disease
EP3102571B1 (en) Substituted pyrimidines useful as egfr-t790m kinase inhibitors
KR101365480B1 (ko) 프로스타글란딘 ｄ2 수용체 길항제의 인산이수소염
US20150299195A1 (en) Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound
HK1207365B (en) Carboxylic acid compounds
CA2804924A1 (en) Substituted pyridine compound

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant